Management of worsening multiple sclerosis with mitoxantrone: a review
- PMID: 16750460
- DOI: 10.1016/j.clinthera.2006.04.013
Management of worsening multiple sclerosis with mitoxantrone: a review
Abstract
Background: Mitoxantrone, an intravenously administered immunosuppressant that inhibits T-cell, B-cell, and macrophage proliferation, is indicated for reducing neurologic disability and relapse frequency in patients with secondary progressive multiple sclerosis (SPMS), progressive relapsing MS, or worsening relapsing-remitting MS (RRMS).
Objective: This article reviews the pathogenesis and natural history of MS and examines the available treatment options for patients with RRMS, worsening RRMS, or SPMS, with a focus on mitoxantrone.
Methods: MEDLINE (1966-present) and the Cochrane Central Register of Controlled Trials (1994-present) were searched for relevant randomized, blinded, controlled clinical trials using the terms mitoxantrone, Novantrone, and multiple sclerosis.
Results: Five randomized, blinded, controlled trials and an ongoing open-label Phase IV safety study were identified and included in this review. In one randomized, double-blind trial (N=25), patients with RRMS who received mitoxantrone 8 mg/m2 monthly had significantly reduced relapse rates at 1 year compared with those who received placebo (P=0.014). In a 2-year, randomized, partially blinded trial (N=51), patients with active RRMS who received mitoxantrone 8 mg/m2 monthly had significantly fewer relapses compared with those who received placebo (P<0.001), and significantly fewer patients had confirmed progression of disability (1-point increase in Expanded Disability Status Scale [EDSS] score) (P=0.02). In a randomized, double-blind trial (N=49), patients with relapsing SPMS who received mitoxantrone 12 mg/m2 monthly for 3 months followed by 12 mg/m2 g3mo for up to 32 months had significant improvements in EDSS scores compared with those who received methylprednisolone 1 g IV monthly for 3 months followed by 1 g IV g3mo (P=0.002 at 1 year, P=0.045 at 2 years) and significant reductions in the number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI) (P=0.002 at 1 and 2 years, P=0.03 at 3 years). In a randomized, partially blinded Phase II trial in 42 patients with active RRMS or SPMS, patients who received mitoxantrone 20 mg IV monthly and methylprednisolone 1 g IV monthly had significantly fewer new gadolinium-enhancing lesions on MRI (P<0.001) and significantly fewer relapses (P<0.01) at 6 months compared with those who received methylprednisolone alone. In a pivotal Phase III trial (N=194), patients with worsening RRMS or SPMS who received mitoxantrone 12 mg/m2 g3mo for 2 years had significantly fewer relapses (P<0.001) and significantly less deterioration in disability, as measured by change in EDSS score (P=0.019), compared with those who received placebo. In a nonrandomized subgroup of patients from this study (n=110), those who received mitoxantrone 12 mg/m2 g3mo had a significant reduction in the number of T2-weighted MRI lesions at 24 months (P=0.027). The most common adverse events in these studies included nausea and/or vomiting (18%-85%), alopecia (33%-61%), amenorrhea (8%-53%), urinary tract infections (6%-32%), and upper respiratory tract infections (4%-53%). Leukopenia was reported in 10% to 19% of patients. Use of mitoxantrone can lead to serious adverse effects, particularly cardiotoxicity, myelosuppression, and, rarely, leukemia. Long-term use of mitoxantrone may compromise left ventricular function. Limited cardiotoxicity was reported in the clinical studies; in the pivotal clinical trial, 2 patients who received mitoxantrone 12 mg/m2 had decreases in left ventricular ejection fraction to <50% of baseline.
Conclusions: In the available clinical trials, mitoxantrone provided effective treatment for worsening RRMS or SPMS. When mitoxantrone is used as recommended, the risks of substantial myelosuppressive and cardiotoxic effects can be reduced by careful patient selection, drug administration, and monitoring. The lifetime cumulative dose should be strictly limited to 140 mg/m2, or 2 to 3 years of therapy.
Similar articles
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.Acta Neurol Belg. 2001 Dec;101(4):210-6. Acta Neurol Belg. 2001. PMID: 11851027 Clinical Trial.
-
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.Ann Neurol. 2001 Mar;49(3):290-7. Ann Neurol. 2001. PMID: 11261502 Clinical Trial.
-
[Long-term effects of glatiramer acetate in multiple sclerosis].Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. Rev Neurol (Paris). 2008. PMID: 18790510 French.
-
[Mitoxantrone].Neurologia. 2003 Jul-Aug;18(6):318-23. Neurologia. 2003. PMID: 12838451 Review. Spanish.
Cited by
-
Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection.Front Med (Lausanne). 2024 Mar 27;11:1364657. doi: 10.3389/fmed.2024.1364657. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38618194 Free PMC article. Review.
-
Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review.Brain Sci. 2023 Dec 20;14(1):4. doi: 10.3390/brainsci14010004. Brain Sci. 2023. PMID: 38275509 Free PMC article. Review.
-
Nonstenotic Carotid Plaques in Ischemic Stroke: Analysis of the STRATIS Registry.AJNR Am J Neuroradiol. 2021 Sep;42(9):1645-1652. doi: 10.3174/ajnr.A7218. Epub 2021 Jul 29. AJNR Am J Neuroradiol. 2021. PMID: 34326103 Free PMC article.
-
Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study.Iran J Neurol. 2018 Apr 4;17(2):64-70. Iran J Neurol. 2018. PMID: 30210730 Free PMC article.
-
S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis.Free Radic Biol Med. 2018 Jun;121:57-68. doi: 10.1016/j.freeradbiomed.2018.04.558. Epub 2018 Apr 22. Free Radic Biol Med. 2018. PMID: 29694854 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical